Multicentric Castleman’s disease in HIV patients: a single-center cohort diagnosed from 2008 to 2018

[1]  K. Nichols,et al.  Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis , 2021, Frontiers in Immunology.

[2]  G. Wertheim,et al.  Increased mTOR activation in idiopathic multicentric Castleman disease. , 2020, Blood.

[3]  S. Pierson,et al.  Increased mTOR activation in idiopathic multicentric Castleman disease , 2019, Clinical Lymphoma Myeloma and Leukemia.

[4]  C. Tomuleasa,et al.  Castleman’s disease in the HIV-endemic setting , 2018, Cancer management and research.

[5]  D. Pinato,et al.  Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. , 2017, Blood.

[6]  C. Hoffmann,et al.  HIV-Associated Kaposi's Sarcoma , 2017, Oncology Research and Treatment.

[7]  S. Lonial,et al.  Emerging treatments in Castleman disease – a critical appraisal of siltuximab , 2016, Biologics : targets & therapy.

[8]  I. Haq,et al.  The clinical application of plasma Kaposi sarcoma herpesvirus viral load as a tumour biomarker: results from 704 patients , 2016, HIV medicine.

[9]  P. Paoli,et al.  KSHV‐associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies , 2015, International journal of cancer.

[10]  S. Steinberg,et al.  Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease. , 2014, Blood.

[11]  K. Naresh,et al.  Diagnostic criteria schemes for multicentric Castleman disease in 75 cases. , 2014, Journal of acquired immune deficiency syndromes.

[12]  S. Nakazawa,et al.  Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases , 2014, Journal of Hematology & Oncology.

[13]  S. Steinberg,et al.  Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease. , 2013, Blood.

[14]  S. Jagannath,et al.  A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease , 2013, Clinical Cancer Research.

[15]  É. Oksenhendler,et al.  Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease. , 2012, Blood.

[16]  R. Tedder,et al.  Can plasma HHV8 viral load be used to differentiate multicentric Castleman disease from Kaposi sarcoma? , 2011, International journal of STD & AIDS.

[17]  J. van Lunzen,et al.  Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease. , 2011, Blood.

[18]  F. Fend,et al.  Plasmablastic lymphoma and related disorders. , 2011, American journal of clinical pathology.

[19]  S. Steinberg,et al.  High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. , 2011, Blood.

[20]  B. Gazzard,et al.  Clinical Features and Outcome in HIV-Associated Multicentric Castleman's Disease. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Bower.  How I treat HIV-associated multicentric Castleman disease. , 2010, Blood.

[22]  T. Powles,et al.  The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  D. Chilton,et al.  Rituximab failure in fulminant multicentric HIV/human herpesvirus 8-associated Castleman's disease with multiorgan failure: report of two cases. , 2008, AIDS.

[24]  S. Montoto,et al.  Brief Communication: Rituximab in HIV-Associated Multicentric Castleman Disease , 2007, Annals of Internal Medicine.

[25]  S. Jessop.  HIV-associated Kaposi's sarcoma. , 2006, Dermatologic clinics.

[26]  L. Moreland.  Humanized anti-interleukin-6 receptor antibody , 2005 .

[27]  J. Molina,et al.  Failure of rituximab in human immunodeficiency virus‐associated multicentric Castleman disease , 2005, American journal of hematology.

[28]  M. Bower,et al.  Fifty years of multicentric Castleman's disease , 2004, Acta oncologica.

[29]  D. Goldstein,et al.  Castleman's disease and HIV infection in Australia , 2004, HIV medicine.

[30]  C. Boshoff,et al.  High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. , 2002, Blood.

[31]  É. Oksenhendler,et al.  High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. , 2000, Blood.

[32]  P. Galle,et al.  IL-6 Receptor Independent Stimulation of Human gp130 by Viral IL-61 , 2000, The Journal of Immunology.

[33]  J. Soulier,et al.  Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients , 1996, AIDS.

[34]  F. Sigaux,et al.  Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. , 1995, Blood.

[35]  B. Castleman,et al.  Case records of the Massachusetts General Hospital: Case No. 40231. , 1954, The New England journal of medicine.

[36]  L. Lekakis,et al.  Multicentric Castleman's disease in HIV infection: a systematic review of the literature. , 2008, AIDS reviews.